Finoriq research workspace
BioAtla, Inc. (BCAB) SEC Filings & Filing Highlights
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective. Review BCAB SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
- Company
- BioAtla, Inc. (BCAB)
- Ticker
- BCAB
- Market Cap
- $6.1M
- Latest Price
- $3.68
- Industry
- Biotech & Pharma
BioAtla, Inc. (BCAB) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for BioAtla, Inc. (BCAB).
| Event | Form | Date |
|---|---|---|
| CERTIFICATE OF MERGER MERGINGBioAtla, Inc., a corporation organized and existing under the Delaware General Corporation Law, does hereby certify | 8-K8.01 | 2026-04-02 |
| BioAtla Reports Fourth Quarter and Full Year 2025 Financial ResultsBioAtla Reports Fourth Quarter and Full Year 2025 Financial Results | 8-K7.01 | 2026-03-31 |
| BioAtla Reports Fourth Quarter and Full Year 2025 Financial ResultsBioAtla Reports Fourth Quarter and Full Year 2025 Financial Results | 8-K2.02 | 2026-03-31 |
| Proposal 1: The Merger ProposalAs previously disclosed, on March 2, 2026, the Company originally convened a special meeting of stockholders (the “Special Meeting”) for th... | 8-K5.07 | 2026-03-23 |
| Arrangements of Certain Officers. Mr. Vasquez and Dr. Sievers Retention Bonuses In lieu of a bo...Arrangements of Certain Officers. Mr. Vasquez and Dr. Sievers Retention Bonuses In lieu of a bonus plan for the first eight months of 2026,... | 8-K5.02 | 2026-03-23 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.